Vanguard Group’s Spero Therapeutics SPRO Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q4 | $4.85M | Buy |
2,083,462
+93,607
| +5% | +$217K | ﹤0.01% | 3263 |
|
|
2025
Q3 | $3.74M | Buy |
1,989,855
+39,474
| +2% | +$86.8K | ﹤0.01% | 3368 |
|
|
2025
Q2 | $5.66M | Buy |
1,950,381
+186,761
| +11% | +$269K | ﹤0.01% | 3170 |
|
|
2025
Q1 | $1.27M | Hold |
1,763,620
| – | – | ﹤0.01% | 3638 |
|
|
2024
Q4 | $1.82M | Hold |
1,763,620
| – | – | ﹤0.01% | 3594 |
|
|
2024
Q3 | $2.36M | Sell |
1,763,620
-6,905
| -0.4% | -$9.26K | ﹤0.01% | 3503 |
|
|
2024
Q2 | $2.3M | Buy |
1,770,525
+117,093
| +7% | +$177K | ﹤0.01% | 3512 |
|
|
2024
Q1 | $2.84M | Buy |
1,653,432
+9,675
| +0.6% | +$15.2K | ﹤0.01% | 3483 |
|
|
2023
Q4 | $2.42M | Buy |
1,643,757
+86,161
| +6% | +$103K | ﹤0.01% | 3536 |
|
|
2023
Q3 | $1.88M | Buy |
1,557,596
+31,122
| +2% | +$43.1K | ﹤0.01% | 3608 |
|
|
2023
Q2 | $2.21M | Buy |
1,526,474
+99,903
| +7% | +$171K | ﹤0.01% | 3620 |
|
|
2023
Q1 | $2.07M | Buy |
1,426,571
+372,183
| +35% | +$623K | ﹤0.01% | 3660 |
|
|
2022
Q4 | $1.82M | Buy |
1,054,388
+665
| +0.1% | +$1.24K | ﹤0.01% | 3694 |
|
|
2022
Q3 | $2.11M | Sell |
1,053,723
-192,269
| -15% | -$191K | ﹤0.01% | 3718 |
|
|
2022
Q2 | $924K | Sell |
1,245,992
-127,936
| -9% | -$372K | ﹤0.01% | 4113 |
|
|
2022
Q1 | $12M | Buy |
1,373,928
+22,550
| +2% | +$231K | ﹤0.01% | 3053 |
|
|
2021
Q4 | $21.6M | Buy |
1,351,378
+58,880
| +5% | +$935K | ﹤0.01% | 2799 |
|
|
2021
Q3 | $23.8M | Buy |
1,292,498
+15,708
| +1% | +$252K | ﹤0.01% | 2766 |
|
|
2021
Q2 | $17.8M | Buy |
1,276,790
+170,094
| +15% | +$2.38M | ﹤0.01% | 2911 |
|
|
2021
Q1 | $16.3M | Sell |
1,106,696
-24,034
| -2% | -$423K | ﹤0.01% | 2896 |
|
|
2020
Q4 | $21.9M | Buy |
1,130,730
+201,832
| +22% | +$3.15M | ﹤0.01% | 2597 |
|
|
2020
Q3 | $10.4M | Buy |
928,898
+193,664
| +26% | +$2.29M | ﹤0.01% | 2765 |
|
|
2020
Q2 | $9.95M | Buy |
735,234
+106,646
| +17% | +$1.2M | ﹤0.01% | 2778 |
|
|
2020
Q1 | $5.08M | Buy |
628,588
+132,187
| +27% | +$1.17M | ﹤0.01% | 2967 |
|
|
2019
Q4 | $4.77M | Sell |
496,401
-286
| -0.1% | -$3.08K | ﹤0.01% | 3189 |
|
|
2019
Q3 | $5.26M | Buy |
496,687
+59,483
| +14% | +$627K | ﹤0.01% | 3124 |
|
|
2019
Q2 | $5.03M | Buy |
437,204
+18,814
| +4% | +$226K | ﹤0.01% | 3173 |
|
|
2019
Q1 | $5.36M | Buy |
418,390
+255,826
| +157% | +$2.71M | ﹤0.01% | 3120 |
|
|
2018
Q4 | $1M | Sell |
162,564
-292,852
| -64% | -$2.37M | ﹤0.01% | 3565 |
|
|
2018
Q3 | $4.79M | Buy |
455,416
+330,580
| +265% | +$3.84M | ﹤0.01% | 3256 |
|
|
2018
Q2 | $1.83M | Buy |
124,836
+13,797
| +12% | +$177K | ﹤0.01% | 3527 |
|
|
2018
Q1 | $1.58M | Buy |
111,039
+65,550
| +144% | +$795K | ﹤0.01% | 3536 |
|
|
2017
Q4 | $534K | Buy |
+45,489
| New | +$558K | ﹤0.01% | 3730 |
|
Other funds holding SPRO
GP
P
AI
AFM
Vanguard Group's SPRO Position: Q4 2025 in Review
Vanguard Group increased its Spero Therapeutics (SPRO) stake by 4.7% in Q4 2025, buying an estimated $217K and bringing the position to 2,083,462 shares worth $4.85M. The position accounts for ﹤0.01% of the portfolio, ranked #3263.
Vanguard Group first reported a position in SPRO in Q4 2017 and has held it in 33 quarters since. The position peaked at $23.8M in Q3 2021. 56 funds tracked by Wall St. Rank hold SPRO as of Q4 2025.
- Vanguard Group held 2,083,462 shares of Spero Therapeutics worth $4.85M as of Q4 2025.
- Vanguard Group bought 93,607 Spero Therapeutics shares in Q4 2025, an estimated $217K.
- Spero Therapeutics made up ﹤0.01% of Vanguard Group's portfolio in Q4 2025, its #3263 holding.
- Vanguard Group first reported a position in Spero Therapeutics in Q4 2017 and has held it in 33 quarters since.
- Vanguard Group's Spero Therapeutics position peaked at $23.8M in Q3 2021.
- 56 funds tracked by Wall St. Rank held Spero Therapeutics as of Q4 2025.
Based on Vanguard Group's 13F filing for Q4 2025, filed 29 Jan 2026.